Trial reportRheumatology international2026
Individualized cognitive-behavioral therapy improves anxiety, depression, sleep quality, hopelessness, and disease severity in fibromyalgia syndrome: a single-blind randomized controlled trial.
Trial report in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Isthmin-1 and Irisin profiles and their association with clinical parameters in fibromyalgia: a cross-sectional study.Rheumatology international · 2026Article
- Therapeutic mechanisms and patients centered outcomes in individualized cognitive behavioral therapy for fibromyalgia syndrome.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study evaluates the effects of individualized cognitive-behavioral therapy (CBT), administered alongside routine treatment, on anxiety, depression, sleep quality, hopelessness, and disease severity in patients with fibromyalgia syndrome (FMS). This is a randomized, controlled, single-blind clinical trial was conducted in a tertiary physical therapy and rehabilitation clinic. Seventy patients who met the 2016 American College of Rheumatology diagnostic criteria were randomized in a 1:1 ratio into an intervention group (n = 35) and a control group (n = 35). The intervention group received a 10-week individualized CBT program administered by a psychologist in addition to routine treatment, while the control group received only routine treatment. Outcomes were assessed using the hospital anxiety and depression Scale (HADS), comprising the anxiety subscale (HADS-A) and the depression subscale (HADS-D), Jenkins sleep scale (JSS), fibromyalgia impact questionnaire (FIQ), and Beck hopelessness scale (BHS) before and after the intervention. A total of 57 patients completed the study, with 23 in the intervention group and 34 in the control group. No significant differences were found between the groups in baseline demographic characteristics and scale scores (p > 0.05). The intervention group demonstrated statistically significant improvements in all scales following treatment: the HADS-A median score decreased from 13.00 to 10.00 (p < 0.001), the FIQ median score decreased from 71.80 to 51.52 (p < 0.001), and the BHS median score decreased from 7.00 to 4.00 (p < 0.001). In contrast, the control group showed no significant changes on any scale (p > 0.05). Individualized CBT, added to routine treatment, addresses anxiety, depression, sleep quality, disease impact, and other issues in FMS patients. Integrating individualized CBT protocols into clinical practice for fibromyalgia management should be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.